NCT01378676 - A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Placebo (Part A)

Placebo tablets once daily for 14 days (Part A)

DRUG

CK-2017357 (Part A)

One 125 mg CK-2017357 tablet once daily for 14 days (Part A)

DRUG

CK-2017357 (Part A)

Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)

DRUG

CK-2017357 (Part A)

Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)

DRUG

Riluzole 50 MG (Part B)

One 50 mg tablet once daily for 14 days (Part B)

DRUG

Placebo (Part B)

Placebo tablets once daily for 14 days (Part B)

DRUG

CK-2017357 (Part B)

One 125 mg tablet once daily for 14 days (Part B)

DRUG

CK-2017357 (Part B)

Two 125 mg tablets once daily for 14 days (Part B)

DRUG

CK-2017357 (Part B)

Three 125 mg tablets once daily for 14 days (Part B)

Trial Locations (9)

10032

Columbia University Medical Center, New York

13210

SUNY Upstate Medical Center, Syracuse

17033

Penn State Hershey Medical Center, Hershey

19107

Drexel University College of Medicine, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

28207

Carolinas Neuromuscular ALS-MND Center, Charlotte

32224

Mayo Florida, Jacksonville

94115

California Pacific Medical Center, San Francisco

06053

University of Kansas, Kansas City